Detalhe da pesquisa
1.
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Br J Cancer
; 127(1): 92-101, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35568736
2.
USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF.
Clin Transl Med
; 14(4): e1648, 2024 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38602256
3.
Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders.
Ophthalmol Sci
; 2(2): 100150, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36249680
4.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Proc Natl Acad Sci U S A
; 105(44): 17079-84, 2008 Nov 04.
Artigo
Inglês
| MEDLINE | ID: mdl-18971340
5.
A Three-Dimensional In Vitro Coculture Model to Quantify Breast Epithelial Cell Adhesion to Endothelial Cells.
Tissue Eng Part C Methods
; 25(10): 609-618, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31441384
6.
RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.
Cancer Res
; 66(20): 10179-87, 2006 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17047083
7.
A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.
Mol Endocrinol
; 20(7): 1633-43, 2006 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-16469774
8.
Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model.
Cancer Res
; 63(16): 4777-80, 2003 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12941793
9.
Activity Based Profiling of Deubiquitylating Enzymes and Inhibitors in Animal Tissues.
Methods Mol Biol
; 1449: 411-9, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27613053
10.
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Cancer Res
; 76(20): 6084-6094, 2016 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27550455
11.
Clinical development of new drug-radiotherapy combinations.
Nat Rev Clin Oncol
; 13(10): 627-42, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27245279
12.
Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection.
Hum Gene Ther
; 16(11): 1267-75, 2005 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-16259560
13.
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Cancer Discov
; 3(1): 68-81, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23103855
14.
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Clin Cancer Res
; 17(4): 783-91, 2011 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21097693
15.
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Cancer Res
; 69(9): 3850-5, 2009 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-19383921
16.
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
J Med Chem
; 51(20): 6581-91, 2008 Oct 23.
Artigo
Inglês
| MEDLINE | ID: mdl-18800822
17.
The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.
Am J Pathol
; 168(4): 1262-75, 2006 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16565500
18.
Quantitative phenotyping as an efficient means to estimate C-cell number in a knock-in mouse model of MEN2B.
Transgenic Res
; 13(4): 339-48, 2004 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-15517993
19.
Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
J Natl Cancer Inst
; 96(16): 1231-9, 2004 Aug 18.
Artigo
Inglês
| MEDLINE | ID: mdl-15316058